Evaluation of the Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00453999
First received: March 27, 2007
Last updated: December 21, 2011
Last verified: December 2011
  Purpose

This study has been designed as a randomized, double-blind, controlled, study to evaluate the efficacy and safety of two once daily intravenous peramivir regimens (200 mg and 400 mg) versus oral oseltamivir phosphate (75 mg twice daily) in hospitalized subjects with acute serious or potentially life threatening influenza. Study treatments will be provided for up to 5 consecutive days.


Condition Intervention Phase
Influenza
Drug: Peramivir
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Multicenter, Randomized, Double-Mask, Double-Dummy Study Comparing the Efficacy and Safety of Peramivir Administered Intravenously Once Daily Versus Oseltamivir Administered Orally Twice Daily in Adults With Acute Serious or Potentially Life-Threatening Influenza

Resource links provided by NLM:


Further study details as provided by BioCryst Pharmaceuticals:

Primary Outcome Measures:
  • Time to resolution of clinical signs of acute influenza in hospitalized patients [ Time Frame: 14 Days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in amount of influenza virus present in nose and throat [ Time Frame: 10 days ] [ Designated as safety issue: No ]
  • Change in frequency and severity of symptoms of influenza [ Time Frame: 14days ] [ Designated as safety issue: No ]
  • Incidence of clinical relapse of influenza after treatment [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Duration of hospitalization [ Time Frame: 14 days ] [ Designated as safety issue: No ]

Enrollment: 137
Study Start Date: March 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment, or
Drug: Peramivir
200mg in 100ml of solution 2 times a day
Experimental: 2
Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL), or
Drug: Peramivir
2: Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL), or
Experimental: 3
Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
Drug: Peramivir
Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18 years of age, male or female
  • Able to provide informed consent, or for whom consent may be provided by guardian
  • Presence of fever at time of screening of ≥ 38.0 o C (≥ 100.0 o F) taken orally, or ≥ 38.5 o C (≥ 101.2 o F) taken rectally. However, this requirement is waived (1) if the subject has a history of fever within the 24 hours prior to screening and has been administered any antipyretic(s) in the 24 hours prior to screening, or (2) if the subject has no history of documented fever as defined above, but reports a symptom of feverishness at some time during the 48 hours prior to screening
  • Presence of at least one respiratory symptom (cough, sore throat, or nasal congestion/symptoms) of any severity (mild, moderate, or severe)
  • Presence of at least one constitutional symptom (headache, myalgia, feverishness, malaise, or fatigue) of any severity (mild, moderate, or severe)
  • Onset of illness no more than 72 hours before presentation. Note: Time of onset of illness is defined as either (1) the time when the temperature (either oral or rectal) was first measured as elevated (at least one degree (°C) of elevation-oral temperature), OR (2) the time when the subject experienced the presence of at least one respiratory symptom AND the presence of at least one constitutional symptom
  • Presence of one or more of the following factors in a subject who is willing to be hospitalized for inpatient observation and treatment:
  • Age ≥60 years
  • Presence of chronic obstructive pulmonary disease (COPD) or other chronic lung disease requiring daily pharmacotherapy
  • History of congestive heart failure with or without medically significant recent change in cardiac status, but without signs or symptoms compatible with NYHA Class IV functional status
  • Presence of diabetes mellitus, clinically stable or unstable
  • Transcutaneous oxygen saturation <94% without supplemental oxygen for at least 5 minutes, or a medically significant decrease in oxygen saturation from an established baseline value
  • Systolic blood pressure <90 mmHg
  • Severity of illness that, in the Investigator's judgment, justifies hospitalization of the subject for supportive care
  • Positive rapid antigen test (RAT) for influenza A and/or influenza B (using an approved test kit) or other test for influenza virus antigen performed in a clinical laboratory at the screening/enrollment evaluation
  • Females of childbearing potential must report one of the following:
  • Be surgically sterile or clinically post-menopausal
  • Have been sexually abstinent 4 weeks prior to date of screening evaluation and be willing to remain abstinent through 4 weeks after study-drug administration for all perimenopausal women or women of child-bearing potential
  • Use oral contraceptives or other form of hormonal birth control including hormonal vaginal rings or transdermal patches and have been using these for 3 months prior through 4 weeks after study-drug administration for all perimenopausal women or women of child-bearing potential
  • Use an intra-uterine device (IUD), or adequate barrier contraception (or double-barrier method such as condom or diaphragm with spermicidal gel or foam) as birth control 4 weeks prior to date of screening evaluation through 4 weeks after study drug administration for all perimenopausal women or women of child-bearing potential

Exclusion Criteria:

  • Immunized against influenza with live attenuated virus vaccine in the previous weeks
  • Treatment with any dose(s) of rimantadine, amantadine, zanamivir, or oseltamivir in the previous 7 days
  • Current clinical evidence of a recognized or suspected acute non-influenzal infectious illness with onset prior to Screening
  • Serum creatinine laboratory result at Screening of >1.6 mg/dL or a result that is >25% above the upper limit of normal for the laboratory performing the test
  • History of clinically significant proteinuria (≥1000 mg/24 hrs)
  • History of moderate or severe renal impairment and/or previous clinical laboratory data indicating an estimated creatinine clearance <50 mL/min during the previous 12 months
  • Electrocardiogram (ECG) at Screening visit showing evidence of acute ischemia, or presence of a medically significant dysrhythmia
  • Presence of cardiac signs or symptoms compatible with NYHA Class III or Class IV functional status for congestive heart failure or angina (see NYHA Appendix V)
  • Presence of diagnosed COPD or other chronic lung condition requiring either continuous or intermittent oxygen therapy as an outpatient. Note: Subjects who are determined to require acute supplemental oxygen therapy at the time of Screening and/or at hospital admission may be enrolled, if exclusion criteria #13 or #14 are not applicable.
  • History of organ transplantation during the previous 12 months
  • Known HIV infection with most recent CD4+ T-cell count ≤350 cells/mL
  • History of diagnosis of any type of cancer (hematologic or solid tumor), that has required chemotherapy or radiation therapy in the previous 12 months, excluding non-melanomatous localized skin cancer
  • Presence of ongoing requirement for chronic mechanical ventilation, either via oral or nasotracheal intubation or via tracheostomy, or chronic or intermittent requirement for BiPAP (bilevel positive airway pressure) at screening. Note: Subjects who require intermittent CPAP treatment for sleep apnea (without oxygen supplementation) may be enrolled
  • Subjects who require acute mechanical ventilatory support of any type at the time of screening.
  • History of alcohol abuse or drug addiction during the previous 12 months
  • Participation in a clinical study of an experimental medication or other treatment during the previous 4 weeks
  • Previous treatment with intravenous or intramuscular peramivir
  • Women who are pregnant (positive serum or urine pregnancy test), who are attempting to become pregnant, or who are breast-feeding
  • Subjects who have been hospitalized due to a condition other than acute influenza and in whom influenza is diagnosed during hospitalization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00453999

  Show 83 Study Locations
Sponsors and Collaborators
BioCryst Pharmaceuticals
  More Information

No publications provided by BioCryst Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: BioCryst Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00453999     History of Changes
Other Study ID Numbers: BCX1812-201
Study First Received: March 27, 2007
Last Updated: December 21, 2011
Health Authority: United States: Food and Drug Administration
Canada: Health Canada
Australia: Human Research Ethics Committee
Hong Kong: Department of Health
New Zealand: Institutional Review Board
Singapore: Health Sciences Authority
South Africa: Medicines Control Council

Keywords provided by BioCryst Pharmaceuticals:
influenza
flu

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Oseltamivir
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on August 18, 2014